Matthew Rhodes

Matthew Rhodes is an experienced medicinal chemist currently employed at Enanta Pharmaceuticals, contributing to drug discovery and scale-up efforts for SARS-CoV-2 antiviral projects since June 2021. Prior experience includes conducting research on the natural product GEX1A at the University of Notre Dame, where a promising role against acute myeloid leukemia and Niemann-Pick type C was explored. As a graduate student researcher, Matthew also synthesized analogues of radicicol at the University of Kansas, demonstrating selective lethality against cancer cell lines. Additional roles include lecturing on organic chemistry topics, an internship at Agios Pharmaceuticals focusing on synthetic route development, and teaching assistant positions at Loyola University Chicago. Education encompasses a PhD in Organic Chemistry from the University of Notre Dame, an MS in Chemistry from Loyola University Chicago, and a BS in Biochemistry.